1187 studies on GLP-1 agonist class curated from PubMed, ClinicalTrials.gov, and EuropePMC. Updated daily.
The key implication of this research is the potential for IDegLira to offer a significantly safer and more effective therapeutic option for Type 2 Diabetes patients transitioning from hospital to home. By reducing the…
The successful demonstration of comparability between different CagriSema delivery devices is a critical step for its future availability and patient accessibility. This Phase 3 study aims to ensure that regardless of…
If CagriSema proves effective, it could represent a significant advancement in managing Chronic Kidney Disease in patients with Type 2 Diabetes and obesity, a population with high unmet medical needs. The potential fo…
This foundational Phase 1 study is critically important as it provides the initial human safety and tolerability data for semaglutide, a potent GLP-1 receptor agonist. Establishing a safe dose range in healthy individ…
As this PHASE 4 clinical trial is currently RECRUITING participants, specific findings are not yet available, with an estimated completion date of 2026-07-01. Researchers are meticulously collecting data from an estim…
This study highlights Kisspeptin-10 as a promising novel therapeutic candidate for the management of obesity and type 2 diabetes. Its multifaceted action, involving both the enhancement of beneficial gut hormones and …
This Phase III clinical trial is crucial because it could validate a new, potentially more accessible or cost-effective semaglutide formulation for obesity treatment. TQF3510 could offer an additional option for patie…
This completed Phase 1 study represents a critical milestone in the development of NNC0113-6856, providing foundational data on its safety and how it behaves in the human body. Establishing a favorable safety and phar…
Tirzepatide has already demonstrated significant efficacy, and exploring higher or alternative dosing strategies could further optimize patient outcomes by potentially enhancing glycemic control and weight loss. This …
The successful completion of this Phase 3 trial is a significant milestone, as Tirzepatide (a dual GIP and GLP-1 receptor agonist) has already demonstrated robust efficacy in adults with Type 2 Diabetes and obesity. I…
This Phase 3b study represents a significant step towards developing more holistic treatment strategies for complex conditions. If successful, combining Mirikizumab and Tirzepatide could offer a novel therapeutic opti…
Tirzepatide offers a powerful new treatment option for Type 2 Diabetes Mellitus, particularly for those struggling to achieve adequate glycemic control with existing therapies. The successful completion of this Phase …
This research provides compelling evidence that GLP-1 receptor agonists may exert direct cardioprotective effects against atrial fibrillation, extending beyond their well-documented benefits in weight management and g…
This study provides compelling evidence that oral semaglutide offers sustained, comprehensive cardiovascular protection beyond glycemic control and weight loss, significantly reducing the risk of major cardiovascular …
This real-world study provides compelling evidence that treatment persistence is a critical determinant for maximizing the comprehensive benefits of Tirzepatide across the spectrum of Cardio-Metabolic-Kidney Syndrome.…
This detailed trial design and baseline data publication is crucial as it lays the groundwork for understanding the potential of Mazdutide as a significant new therapeutic option. If Mazdutide demonstrates superior or…
The substantial and clinically meaningful weight loss achieved with once-weekly Mazdutide positions it as a highly promising therapeutic agent for obesity and overweight. The dual agonism of GLP-1 and GIP receptors ap…
The first approval of Mazdutide in China is a pivotal development, introducing a novel dual glucagon receptor (GcgR) and glucagon-like peptide-1 receptor (GLP-1R) agonist to the therapeutic landscape. This provides a …
This case report provides crucial preliminary evidence supporting the potential of Mazdutide as a comprehensive treatment option for adolescents grappling with the complex interplay of obesity, type 2 diabetes, and hy…
This paper primarily details the demographic and clinical characteristics of the study population at the start of the trial. The cohort comprised a diverse group of individuals with obesity, with an average age of 49.…
This pilot study provides compelling preliminary evidence that liraglutide could offer a novel therapeutic approach for sleep apnea in non-diabetic individuals, potentially independent of its weight-loss effects. The …
This study highlights the potential of Mazdutide as a highly effective treatment option for type 2 diabetes, particularly in the Chinese adult population, addressing both glycemic control and significant weight manage…
This comprehensive evaluation provides critical evidence supporting the superior efficacy of certain long-acting GLP-1 RAs in managing Type 2 Diabetes, particularly concerning glycemic control and weight reduction. Th…
This comprehensive network meta-analysis provides compelling evidence that anti-diabetic agents are not only effective in managing diabetes but also hold significant promise for treating MASH, a condition with limited…
This study highlights Mazdutide's multifaceted therapeutic potential for MASLD, demonstrating its ability to simultaneously improve lipid metabolism, reduce inflammation, and alleviate cellular stress. The significant…
Survodutide's dual agonism represents a significant advancement, offering a multi-faceted approach to treating complex cardiometabolic diseases by simultaneously targeting weight loss, glycemic control, and hepatic st…
Understanding the baseline characteristics of participants in a large Phase 3 trial is crucial for interpreting the future efficacy and safety results, ensuring the findings are generalizable to the target patient pop…
This research boldly underscores the critical role of hepatic GCGR in mediating the profound metabolic benefits of dual GLP-1R/GCGR agonists like survodutide. Understanding this mechanism could lead to the development…
This research provides crucial insights into the central mechanism of action for Survodutide, demonstrating its direct engagement with brain regions critical for appetite regulation. Understanding that Survodutide act…
This case report highlights a rare but significant potential adverse effect of semaglutide, suggesting that it might induce hypercapnia even in individuals with healthy lungs. This finding is critical as it expands th…
The successful completion of this Phase 1/2 trial for IBI362 could significantly impact the landscape of obesity treatment, particularly for the Chinese patient population. If IBI362 demonstrates a favorable safety pr…
This research establishes selective amylin receptor agonism as a powerful new therapeutic strategy for metabolic diseases, potentially offering superior benefits over existing incretin-based therapies. The distinct me…
This blueprint provides a standardized, multi-faceted approach to evaluating the long-term efficacy of novel anti-obesity treatments like survodutide, moving beyond simple weight loss metrics. By focusing on disease m…
This proactive optimization of the SYNCHRONIZE™ Phase 3 program for survodutide is crucial for accelerating the development and availability of new obesity treatments. By identifying potential bottlenecks and effectiv…
This review underscores the significant therapeutic potential of survodutide as a novel treatment for both obesity and MASH, leveraging its unique dual GLP-1 and glucagon receptor agonism. Its ability to induce substa…
This research highlights critical areas for intervention to optimize patient education and improve outcomes for individuals using Saxenda®. Addressing the identified barriers, such as time constraints and lack of stan…
If successful, this study could establish Mazdutide as a promising new therapeutic option for Alcohol Use Disorder (AUD), potentially offering a novel mechanism of action (via GLP-1/GIP agonism affecting reward pathwa…
PCOS is a complex condition with significant unmet medical needs, particularly for obese patients struggling with hyperandrogenism and metabolic dysfunction. If Mazdutide proves effective in reducing FAI, it could rep…
Understanding how renal impairment affects IBI362's pharmacokinetics is critically important for patient safety and treatment efficacy. If kidney function significantly alters drug exposure, dose adjustments will be n…
Optimizing drug formulation is crucial for enhancing patient convenience, adherence, and ultimately, therapeutic efficacy for conditions like obesity and MASH. If Formulation B2 demonstrates superior or comparable bio…
This Phase II trial provides compelling evidence that Survodutide could be a highly effective and much-needed therapeutic option for NASH and liver fibrosis, addressing a significant unmet medical need. The observed d…